Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda added to CyBorD in newly diagnosed multiple myeloma
NCT04258683Phase 2Withdrawn
- Sponsor
- Canadian Myeloma Research Group
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM), sponsored by Canadian Myeloma Research Group. Planned start Feb 2021; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04258683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258683.